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Neuroblastomas (NB) are neuroectodermal tumors that account for 15% of all childhood cancer 
deaths. Different prognostic factors including age, stage and amplification of MYCN (MYCNampl), are 
critical for defining NB risk and for guiding therapeutic choices1. In this context, although different 
strategies have been approached, the prognosis of high-risk neuroblastoma (NB) remains poor due 
the high frequency of relapse which not only occurs at the primary tumor site but frequently arises in 
the bone marrow. Thus, in vivo, neuroblastoma exploits different mechanisms to escape the immune 
surveillance2. These might include the so called “adaptive immune resistance” characterized by the 
de-novo expression of Programmed Death Ligands (PD-Ls)3 induced by IFN-γ whose storm occurs 
after different immunotherapeutic approaches. In the present study we analyzed the constitutive and 
the inducible surface expression of PD-Ls in NB cells. We showed that PD-L1 is constitutively express 
by virtually all HLA class Ipos NB cell lines, whereas PD-L2 is rarely detected. Moreover PD-L1 could 
be acquired/upregulated in both NB cell lines and NB engrafted nude/nude mice. Importantly, after 
IFN-γ stimulation, PD-L1 can be expressed by metastatic neuroblasts isolated from bone marrow 
aspirates of high-risk NB patients, characterized by different MYCN amplification status. Interesting-
ly, in one case, metastatic neuroblasts were poorly responsive to IFN-γ stimulation, suggesting that 
responsiveness to IFN-γ might represent a further element of heterogeneity in metastatic neuroblasts. 
Finally, we documented the presence of PD-1-positive lymphocytes in NB-infiltrated bone marrow of 
patients. These cells are mainly represented by aβ T cells but also include small populations of gδ T 
cells and NK cells. Moreover, PD-1pos T cells expressed higher levels of activation markers as com-
pared to the negative counterpart. Overall our data show that a PD-L1-mediated immune resistance 
mechanism might occur in metastatic neuroblasts and provide a biological rationale for blocking the 
PD-1/PD-Ls axis in future combined immunotherapeutic approaches.
This work was supported by Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.) (Investi-
gator Grant 15704 and special project 5x1000 9962), Ministero dell’Istruzione, dell’Università e della 
Ricerca (M.I.U.R) (PRIN 20103FMJEN) and Ministero della Salute (5 x 1000 e Ricerca Corrente) and 
Equipe FRM DEQ20140329534. 
References
1. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma 
Risk Group (INRG) classification system: an INRG Task Force report. Journal of clinical oncology : official jour-
nal of the American Society of Clinical Oncology 2009; 27:289-97.
2. Bottino C, Dondero A, Bellora F, Moretta L, Locatelli F, Pistoia V, et al. Natural Killer Cells and Neuroblastoma: 
tumor recognition, escape mechanisms and possible novel immunotherapeutic approaches. Front Immunol (in 
press) 2014.
3. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews Cancer 2012; 
12:252-64.
Keywords
Anti-tumor immunity; Immune checkpoints; Neuroblastoma; Natural Killer cells; T cells; PD-1; 
PD-L1; PD-L2; INF-γ TNF-a.
